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Section 2: Introduction and objectives 
Plantar fasciopathy has a lifetime prevalence of 10%. Patients suffer from sharp pain under the heel, 
often for several months or years. Multiple treatments are available, but no single treatment appears 
superior to the others. A corticosteroid injection offers short-term pain relief but is no better than 
placebo in the longer term (>8 weeks). Heavy-slow resistance training has shown potentially 
positive effects on long-term outcomes (>3 months) and combining exercises with an injection may 
prove to be superior to exercises alone. However, the effect of heavy-slow resistance training 
compared with a simpler approach of patient advice (e.g. load management) and insoles is currently 
unknown. This trial compares the efficacy of patient advice (PA) versus patient advice plus heavy-
slow resistance training (PAX) versus patient advice plus heavy-slow resistance training plus a 
corticosteroid injection (PAXI) in improving the Foot Health Status Questionnaire pain score after 
12 weeks in patients with plantar fasciopathy. 
 
Section 3: Study methods 
3.1: Ethical statement 
The trial is being conducted according to the Declaration of Helsinki III, and the protocol, template 
informed consent forms, and participant information were approved by the Ethics Committee of 
North Denmark Region (N- 20180066) prior to the inclusion of participants. All participants 
provide informed consent before enrolment. When participants sign the consent form, they agree 
that they have been adequately informed about the purpose, methods, advantages, and 
disadvantages of participation; they know that participation is voluntary; and they can withdraw 
from the trial without losing their current or future rights to receive treatment. 
 
3.2: Study design 
The FIX-Heel Trial is designed as a randomised, superiority trial with a 3-group parallel design. 
The preparation of the trial, including publishing this trial protocol, was done in accordance with 
the PREPARE Trial guide.(1)Before the inclusion of the first participant, the trial was registered on 
clinicaltrials.gov (NCT03804008). 
 
3.3: Randomisation 
Participants will be stratified by sex and block randomised in random concealed block sizes of 3 to 
12 (1:1:1) into three parallel groups. A researcher not involved in the trial generated the allocation 
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sequence using a random number generator on www.sealedenvelope.com and is the only person 
who knows the block sizes. The researcher was trained by the project manager in generating 
allocation sequences and the process was piloted. 
 
The randomisation is coded so that the project manager does not know which intervention is linked 
to which group number (Group 1, 2 or 3). The envelopes will be kept in a locked room at Aalborg 
University Hospital where only the two physiotherapists involved in baseline testing have access. 
The randomisation schedule was prepared at the Center for General Practice at Aalborg University 
by a person not involved in the actual trial. The notes in the envelopes state both group number and 
intervention and the physiotherapists responsible for assessing participants and delivering the 
interventions will not be aware of the coding before they open the first envelopes. In practice, after 
a participant has been enrolled, has filled out questionnaires and received initial patient advice and 
information regarding the practicalities of participation, the physiotherapist will take an envelope 
and assign the participant to the allocated treatment based on randomisation. 
 
3.4: Sample size 
The minimal important difference of the FHSQ pain domain has been found to be either 12.5 or 
14.1 points in this patient population.(2,3) We have chosen the most conservative option (i.e. 14.1 
points) to form the basis of the sample size calculation. Based on a standard deviation of 22 points, 
which is comparable to the overall standard deviations found in previous studies of this patient 
population (4–7), a two-sided 5% significance level and a power of 90%, a sample size of 53 
participants in each group will be necessary. Taking into consideration possible drop-outs, we will 
include 60 participants in each group and, thus, a total sample size of 180 participants. 
Section 4: Statistical principles 
We will report two-sided 95% confidence intervals and P-values <0.05 are interpreted as 
statistically significant. We will use Q-Q plots and histograms to assess data normality and analyses 
are performed following the intention-to-treat principle such that  randomised  participants  will  be  
analysed  according  to  the  treatment  group   to   which   they   were   originally   assigned,   
regardless   of   treatment   received, crossover or non-adherence. The data analyst will be blinded 
to the interventions received in each group and remains unblinded until after the primary analysis 
has been performed. Data is collected and stored in REDCap (Vanderbilt University, Nashville, TN, 
USA). Data will be exported to Microsoft Excel (Microsoft Corporation, Washington, USA) where 
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it they will be prepared for analyses will be performed in SPSS (IBM Corporation, New York, 
United States). 
Section 5: Study population 
5.1: Eligibility criteria 
The inclusion criteria are: history of inferior heel pain for at least three months before enrolment; 
pain on palpation of the medial calcaneal tubercle or the proximal plantar fascia; thickness of the 
plantar fascia ≥4.0 mm and; mean heel pain of ≥30 mm on a 100 mm VAS during the previous 
week. The exclusion criteria are: below 18 years of age; diabetes; history of inflammatory systemic 
diseases (e.g. rheumatoid arthritis or spondyloarthritis)(4); prior heel surgery; pregnancy or 
breastfeeding; corticosteroid injection specifically for PF within the previous six months; pain or 
stiffness in the 1st metatarsophalangeal joint to an extent where the exercises cannot be performed; 
known hypersensitivity to corticosteroids or local anaesthetics; skin or soft tissue infection near the 
injection site; received any treatment by a healthcare professional for PF within the previous 12 
weeks; or made any substantial changes to usual self-care of the condition in the last 4 weeks (e.g. 
started using insoles, started performing stretching, made a substantial decrease in physical activity 
level). These criteria are in line with those of similar studies in this patient population.(4,8,9) These 
criteria lead to a representative sample of patients with PF as previous studies include the majority 
of potentially eligible participants.(4,8,9) 
 
5.2: Baseline characteristics 
Characteristic Unit Reporting 
Sex Male/Female Frequency 
Height Cm Mean (Standard deviation) 
Weight Kg Mean (Standard deviation) 
Body mass index Kg/m2 Mean (Standard deviation) 
Symptom duration Months Mean (Standard deviation) 
Pain during past week mmVAS Mean (Standard deviation) 
Bilateral pain Yes/No Frequency 
Plantar fasciopathy incidents Number of incidents Frequency 
Plantar fascia thickness mm Mean (Standard deviation) 
Educational level n/a Frequency 
Job situation n/a Frequency 
Days of sick leave Days Mean (Standard deviation) 
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Contact to healthcare 
practitioners 
n/a Frequency 
Previous treatment n/a Frequency 
Comorbidities n/a Frequency 
Section 6: Analysis 
6.1: Experimental outcomes 
The primary outcome is the pain domain of the Foot Health Status Questionnaire (FHSQ) at the 12-
week follow-up. The FHSQ is a questionnaire ranging from 0 (worst possible score) to 100 (best 
possible score) with a high reliability (ICC=0.74-0.92) that assesses multiple dimensions of foot-
related health and function and is recommended in this patient population.(10,11) The minimal 
important difference of the pain domain is 14.1 points.(2) We will use a Danish validated 
translation of the original questionnaire.(12) 
 
Secondary outcomes include: i) the other domains of the FHSQ (function, footwear and general foot 
health domains), ii) Global Rating of Change (GROC), iii) PASS, iv) Pain Self-Efficacy 
Questionnaire (PSEQ), v) weekly light, moderate and vigorous physical activity level, and to 
perform a cost-effectiveness analysis vi) EQ-5D-5L, and vii) patients’ co-payments and other 
condition-related expenses. 
 
• We will use the GROC to measure participants’ self-reported improvement on a 7-point 
Likert scale ranging from “much improved” to “much worse”. Participants are dichotomised 
as improved if they rate themselves as “much improved” or “improved” (categories 6 and 7) 
and categorised as not improved if they rate themselves from “slightly improved” to “much 
worse” (categories 1 to 5).  
• PASS (Yes/No) will be used as a measure of when participants achieve a self-evaluated 
satisfactory result and feel no need for further treatment. Therefore, this is not necessarily a 
measure of complete recovery as some may be satisfied despite still experiencing symptoms. 
PASS has been used to evaluate clinically relevant states in PF and in other musculoskeletal 
disorders and post-operative pain.(9,13–15) Participants will be asked to report to the 
physiotherapists as soon as they experience PASS and the date will be noted. Furthermore, 
participants will be asked about their PASS status during follow-ups. After the participant 
reports a PASS, they will be instructed to continue performing the exercise as prescribed for 
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at least four weeks and to report back if their PASS status changes (i.e. if the condition 
deteriorates and they would need treatment again).  
• The PSEQ measures pain self-efficacy and provides a score ranging from 0 (not at all 
confident) to 60 (completely confident) with lower scores indicating lower self-efficacy.(16) 
The Danish version of the PSEQ has been validated in a Danish chronic pain population and 
has a high reliability (ICC=0.89).(17) 
• To estimate weekly physical activity level expressed as Metabolic Equivalents (METs), we 
will use 3D accelerometry. Participants will be given a wrist-worn accelerometer 
(ActiGraph wGT3X-BT (ActiGraph LLC, Pensacola, FL, USA)) during baseline and will be 
asked to wear this during the first three weeks after baseline and then return the 
accelerometer in a postmarked envelope. During the 12-week follow-up, participants receive 
the accelerometer again and will be wearing it for an additional three weeks before returning 
it. Participants will be instructed to wear the accelerometer at all times. We will use data 
from the first valid week recorded during the first and second round of wearing the 
accelerometer (i.e. one week during weeks 1 to 3, and one week during weeks 13 to 15). A 
valid week is defined as ³4 days of ³10 hours of wear time.(18) Data will be extracted from 
the accelerometers using the ActiLife software and divided into light (<3 METs), moderate 
(3–6 METs), and vigorous (>6 METs) physical activity.(19) 
• The Danish version of the EQ-5D-5L is a generic tool for measuring health-related quality 
in life and will be used to estimate QALYs and perform a cost-effectiveness analysis. It 
consists of five dimensions (mobility, self-care, usual activities, pain/ discomfort and 
anxiety/depression) that each have five ranked response options ranging from no problems 
or concerns to largest possible problems or concerns. 
• Patients’ co-payments and other condition-related expenses are estimated based on a 
questionnaire with questions about sick leave, loss of productivity due to PF, co-payments 
for treatments and/or equipment and medication. 
 
6.2: Statistical methods 
Primary analysis 
The primary analysis will investigate the between-group difference in FHSQ pain. We will visually 
explore the trajectory of improvements before applying the statistical model to the data. This will 
ensure our choice of model match the specific trajectories. We will use a linear mixed effects model 
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with the participant as random effect. The baseline value, time (4, 12, 26 and 52 weeks), group 
allocation (PA or PAX or PAXI) and term for interaction between time and group will be treated as 
fixed-effect variables. Conclusions will only be drawn based on differences or the lack hereof at the 
primary endpoint (12 weeks). 
 
Secondary analyses 
We will also analyse the mean values of the secondary continuous outcomes (other domains of 
FHSQ, PSEQ and physical activity level (light, moderate, and vigorous)) using linear mixed models 
with participant as random effect. The baseline value, time (4, 12, 26 and 52 weeks), group 
allocation (PA or PAX or PAXI) and term for interaction between time and group will be treated as 
fixed-effect variables. The risk difference (  - 
 ) will be calculated for the dichotomised GROC to determine the 
probability of being improved, for the PASS (Yes/No) to determine the probability of achieving a 
self-evaluated satisfactory result within the 12, 26 and 52 weeks of intervention We will also 
calculate risk differences to determine the probability of experiencing a deterioration of PF defined 
as a decrease in FHSQ pain of the minimal important difference ( ≥14.1 points) from one follow-up 
to another, or changing ones status from having achieved PASS to no longer having achieved 
PASS. We will calculate the number needed to treat for the primary outcome at the primary 
endpoint as 1/risk difference. We will use a Kaplan-Meier survival analysis and compare survival 
curves using logrank tests to investigate between-group differences in time to achieving 
PASS.(20,21) If a participant changes PASS multiple times (e.g. achieving PASS before 12 weeks, 
reporting not to have achieved PASS at 26 weeks and then having achieved PASS again at the 52-
week follow-up), only time to the first PASS achieved is used in the analysis. To explore the 
association between exercise compliance and FHSQ pain-score we will use Pearson’s correlation 
coefficient and we will use an unpaired t-test to explore between-group differences in exercise 
compliance between the PAX and PAXI groups. 
 
Cost-effectiveness analysis 
The reporting of the economic evaluation will follow the Consolidated Health Economic Evaluation 
Reporting Standards (CHEERS) checklist for a more transparent and complete reporting of methods 
and findings.(22) For each intervention, mean values (and standard errors of the mean) will be 
reported for the main categories of estimated costs and QALYs, as well as mean differences 
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between the comparator groups. Probabilistic sensitivity analyses will be used to estimate the 
decision uncertainty and calculate incremental cost-effectiveness ratios. 
 
Exclusion cohort 
Potential participants who are excluded during the physical examination and eligible participants 
who decide to withdraw before randomisation will be asked to be part of a concurrent observational 
cohort. These participants receive the same questionnaires as the participants of The FIX-Heel Trial 
with the addition of a questionnaire about care-seeking behaviour and treatments received during 
the time between the last follow-up and the current. We will use the same follow-up times (4, 12, 26 
and 52 weeks) as in The FIX-Heel Trial, however, all follow-ups will be conducted through e-mail. 
We will report the outcome data of the follow-ups descriptively with means and standard deviations 
for continuous outcomes and frequencies for categorical outcomes. 
 
 
6.3: Harms 
Participants will be asked to report any adverse events to the physiotherapists immediately after 
they occur by either telephone, SMS or e-mail. Expected adverse events due to the injection are 
plantar fascia rupture, signs of infection (e.g. fever and local swelling and redness), and local pain 
in the area of injection lasting more than 48 hours after injection. Adverse events after the 
palpation-guided injection are rare and two trials that used ultrasound-guided injections reported no 
adverse events occurred.(4,23,24) No stopping rules are planned. Expected adverse events due to 
the exercise are injuries to the musculoskeletal system such as muscle tears, muscle strains, a 
sprained joint, injury from falling or exacerbation of symptoms related to PF, delayed onset muscle 
soreness equal to or greater than 20 mm on a 0 to 100 mm VAS that lasts for more than 48 hours 
after performing the exercises or exacerbation of PF.  
 
Adverse events will be graded 1 to 5 according to the Common Terminology Criteria for Adverse 
Events v4.03.(25) A medical doctor specialised in either rheumatology or general medicine will 
assess and grade the adverse event and ultimately have the decision whether the participant should 
be withdrawn from the trial due to the adverse event. If the adverse event is a grade 1 (mild), the 
participant may be allowed to skip one or two training sessions without any assessment. If the 
adverse event recurs after having skipped the exercise, the participant will have to be assessed by 
the medical doctor before participation in the trial is continued. If a participant experiences an 
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adverse event and requests withdrawal from the study, data until the last exercise activity before the 
adverse event occurred will be included in the analyses. The physiotherapists will report any 
incidents to the sponsor as quickly as possible and no later than 15 days after the participant 
reported the event. Sponsor will report any severe adverse events (grade 3-5) to the Ethics 
Committee of North Denmark Region no later than seven days after being informed. All adverse 
events will be reported in the future reporting of the trial. Any participants who suffer harm from 
trial participation will receive compensation by The Patient Compensation Association. 
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